Comparative Pharmacology
Head-to-head clinical analysis: KERLEDEX versus PEDIAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLEDEX versus PEDIAZOLE.
KERLEDEX vs PEDIAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Pediazole is a combination of erythromycin (a macrolide antibiotic that binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis) and sulfisoxazole (a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis).
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
Adults: 1 mg/kg intravenously every 6 hours.
None Documented
None Documented
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
Terminal half-life is approximately 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment.
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Renal excretion of unchanged drug accounts for approximately 70-80% of the dose; biliary/fecal elimination is minor (<10%).
Category C
Category C
Corticosteroid/Antibiotic Combination
Antibiotic Combination